Research programme: lysosomal acid lipase - Large Scale Biology Corporation
Latest Information Update: 02 Oct 2021
At a glance
- Originator University of Cincinnati
- Developer Large Scale Biology Corporation (CEASED)
- Class Cardiovascular therapies
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 23 Dec 2005 Large Scale Biology Corporation ceased operations
- 23 Sep 2005 Large Scale Biology Corporation and Icon Genetics announced the initiation of the commercial phase of their collaborative agreement for an undisclosed product for enzyme replacement therapy
- 01 Aug 2005 Lysosomal acid lipase has received orphan drug status in the USA